RecruitingNot ApplicableNCT07125235

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial

Sponsor

University of California, San Francisco

Enrollment

270 participants

Start Date

Feb 9, 2026

Study Type

INTERVENTIONAL

Conditions

Behavioral Intervention Viral Suppression of HIV Infection ART Adherence

Summary

Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This trial (reSTART) is testing a reactive support system — using smartphone-based tools including urine self-testing and remote check-ins — to improve HIV medication adherence in people living with HIV who use stimulants (like methamphetamine or cocaine) and are not fully suppressing the virus. **You may be eligible if...** - You are living with HIV and prescribed antiretroviral therapy (ART) with a tenofovir-based regimen - You have a detectable viral load, evidence of missed doses (by urine testing), or you self-report less than perfect adherence - You use stimulants - You have a U.S. mailing address and a smartphone with a camera **You may NOT be eligible if...** - You are not currently prescribed ART - You have a serious health condition that would interfere with participation - You are unwilling to do urine self-testing or viral load monitoring - You cannot provide a hair sample for drug monitoring purposes Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALreSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention

The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.

DEVICEurine tenofovir point-of-care self-test

urine tenofovir point-of-care self-test